Clinical experience with the uterine progesterone system (Progestasert R)
Zador, G.; Nilsson, B.A.; Nilsson, B.; Sjöberg, N.O.; Weström, L.; Wiese, J.
Contraception 13(5): 559-569
1976
ISSN/ISBN: 0010-7824 PMID: 1261259 DOI: 10.1016/0010-7824(76)90012-3Document Number: 466751
The results of a joint project from Sweden and Denmark, in which a T-shaped IUD was selected for study is reported. The drug delivery system was developed to release progesterone at 65 mcg/day for 1 year. 150 women from 3 clinics, of whom 115 were multiparous and 35 nulliparous, were studied for 1598 woman-months. In 36% of the multiparous women, insertions were made 2-3 months after parturition. Increases in the duration of menstrual flow were noted after 6 and 12 months. Dsymenorrheic pains were decreased after use of the uterine progesterone system. Continuation rates were 84.4 for multipara and 80.2 for nulliparas. The most frequent reasons for removal were spotting and bleeding. After 1 year of use 3 pregnancies occurred 2 of them ectopic, a rate of 2.1/100 woman-years. Pelvic inflammatory disease was found in 4 patients. Endometrial biopsies in 10 cases, taken after 12 months of exposure, showed early decidual changes, gland suppression, and vascular variations. 4 patients were lost to follow-up. The Progestasert is considered a favorable alternative to other bioactive IUDs. Further studies are recommended.